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RE: A two-gene expression ratio predicts clinical outcome
in breast cancer patients treated with tamoxifen
We recently reported a novel biomarker of two-gene expression
ratio that outperformed the current positive and negative predictors
of outcome in patients with estrogen receptor (ER)-positive early-
Dennis C. Sgroi,1,2,* Daniel A. Haber,1stage breast cancer treated with adjuvant tamoxifen (Ma et al.,
Paula D. Ryan,1 Xiao-Jun Ma,32004). While the cases in our original 60-patient discovery cohort
and Mark G. Erlander3were closely matched for tumor size, grade, and lymph node
status (28 cases node-negative, 25 node-positive and 7 cases not
1Department of Pathology, Harvard Medical Schoolevaluated), almost all cases (19/20) in the initial validation cohort
Molecular Pathology Research Unitwere lymph node-negative. The bias toward lymph node-negative
Massachusetts General Hospitalpatients in our initial validation cohort was not by design, but was Boston, Massachusetts 02129
consistent with the fact that lymph node-positive patients usually 2 Massachusetts General Hospital Cancer Center
receive chemotherapy in addition to adjuvant tamoxifen (EBCTCG, Harvard Medical School
Boston, Massachusetts 021291998) and would have been excluded from our study. Subsequent
3 Arcturus Bioscience, Inc., 400 Logue Avenueto this publication, we have further assessed the predictive power
Mountain View, California 94043of this two-gene ratio biomarker in an independent cohort of breast
*Correspondence: dsgroi@partners.orgcancer patients from a randomized prospective clinical trial of
adjuvant tamoxifen (D. Sgroi et al., 2004, ASCO Annual Meeting References
Proceedings, abstract). Results from this study confirm our initial
Ma, X.J., Wang, Z., Ryan, P.D., Isakoff, S.J., Barmettler, A., Fuller, A., Muir,observations and suggest that the two-gene signature is a more
B., Mohapatra, G., Salunga, R., Tuggle, J.T., et al. (2004). A two-gene expres-robust predictor in lymph node negative patients, as compared
sion ratio predicts clinical outcome in breast cancer patients treated with
with lymph node positive patients. We are currently carrying out tamoxifen. Cancer Cell 5, 607–616.
additional studies using archived tissue samples from large ran-
Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). (1998). Tamox-
domized prospective trials of adjuvant tamoxifen to further evaluate ifen for early breast cancer: An overview of the randomized trials. Lancet
351, 1451–1467.the clinical utility of our gene expression ratio biomarker.
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